Pfizer says COVID-19 vaccine “highly effective” against Delta variants

Mufid Majnun/Unsplash

The Pfizer/BioNTech novel coronavirus (COVID-19) vaccination is “highly effective” against the Delta variant, Reuters reported late last week.

The variant, which was first identified in India, has become the predominant strain in England and other countries, and is on track to become the predominant strain in the United States, researchers said.

A recent study by researchers at the University of Texas with Pfizer/BioNtech published in the journal Nature found that antibodies elicited by the vaccine were still able to neutralize all tested variants, including Delta, but at reduced strength. Additionally, an analysis by Public Health England found that both the Pfizer/BioNTech and AstraZeneca vaccines provide more than 90 percent protection against hospitalization from the Delta variant. More research is needed.

Editor's note: Click here for more information and ongoing COVID-19 updates for integrative healthcare professionals.